Immunovant is developing batoclimab, a monoclonal antibody currently in a Phase IIa trial (NCT05907668 ... a small molecule therapy that targets and degrades immunoglobulin G1 (IgG1) autoantibodies ...

The US Food and Drug Administration (FDA) has approved a pre-filled syringe version of argenx’s Vyvgart, giving generalised ...

Sanofi and Teva Pharmaceuticals have reported that the Phase IIb RELIEVE UCCD study of the human IgG1-λ2 monoclonal antibody targeting TL1A, duvakitug, met its primary endpoints in patients with ...